Hematology Practice Questions

Q: What is an indication for intramuscular iron therapy?

Oral iron intolerance. The primary indication for parenteral iron therapy (Intramuscular or Intravenous) is the inability of the patient to tolerate or absorb oral iron [1]. **1. Why "Oral iron intolerance" is correct:** Oral iron often causes significant gastrointestinal side effects, such as epigastric pain, nausea, constipation, or diarrhea. In patients where these side effects lead to non-compliance, or in conditions like inflammatory bowel disease (IBD) or malabsorption syndromes (e.g., Celiac disease, post-gastrectomy) [3], parenteral iron is the treatment of choice to replenish iron stores effectively. **2. Why the other options are incorrect:** * **Pregnancy & Postpartum period:** Oral iron is the first-line treatment for iron deficiency anemia in these stages [2]. Parenteral iron is reserved only for severe anemia in the late third trimester or if oral iron fails/is not tolerated. * **Emergency surgery:** In an emergency surgical setting with significant anemia, iron therapy (oral or parenteral) is too slow to take effect (requiring weeks for hemoglobin rise). The treatment of choice here is **Packed Red Blood Cell (PRBC) transfusion** for immediate stabilization. **Clinical Pearls for NEET-PG:** * **Z-track technique:** Intramuscular iron (Iron Dextran) must be administered using the Z-track technique to prevent skin staining and "tattooing." * **IV vs. IM:** Intravenous iron is now generally preferred over Intramuscular iron due to the risk of local pain, sterile abscesses, and unpredictable absorption associated with IM injections. * **Calculation:** The total dose of iron required is calculated using the **Ganzoni Formula**: * *Total Iron Deficit (mg) = Body weight (kg) × (Target Hb - Actual Hb) × 2.4 + Iron stores (500 mg).*

Q: Paroxysmal Nocturnal Hemoglobinuria (PNH) is screened by which of the following tests?

Acid ham test. **Explanation:** **Paroxysmal Nocturnal Hemoglobinuria (PNH)** is an acquired clonal hematopoietic stem cell disorder caused by a mutation in the **PIGA gene**, leading to a deficiency of GPI-anchored proteins (specifically **CD55 and CD59**). These proteins normally protect RBCs from complement-mediated lysis [1]. 1. **Why Option A is Correct:** The **Acid Ham Test (Acidified Serum Lysis Test)** is the classic confirmatory/screening test for PNH. It relies on the principle that PNH cells are hypersensitive to complement. When the patient's RBCs are placed in acidified serum (pH 6.4), the alternative complement pathway is activated, leading to the lysis of the defective PNH cells. 2. **Why Other Options are Incorrect:** * **Option B:** The **Sucrose Lysis Test** was historically used as a screening test because sucrose promotes the binding of complement to RBCs. However, it is less specific than the Ham test and has been largely phased out. * **Option C & D:** Serum haptoglobin (not hapten) levels are decreased in any intravascular hemolysis, and serum complement levels are typically normal in PNH; these are non-specific findings and not used for screening. **Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** **Flow Cytometry** is now the investigation of choice. It detects the absence of CD55 (DAF) and CD59 (MIRL) on RBCs and leukocytes. * **FLAER (Fluorescent Proaerolysin):** A highly sensitive flow cytometry-based test used to detect the absence of GPI anchors. * **Triad of PNH:** Hemolytic anemia, Pancytopenia, and Venous Thrombosis (often in unusual sites like the Budd-Chiari syndrome). * **Treatment:** **Eculizumab** (a monoclonal antibody against C5 complement) is the drug of choice.

Q: A 23-year-old female presents with a 2-year history of anemia and jaundice. A peripheral smear shows spherocytes. What is the most appropriate investigation to perform?

Coombs test. **Explanation:** The clinical presentation of anemia, jaundice, and spherocytes on a peripheral smear suggests **Spherocytosis**. In clinical practice, the two primary differentials for spherocytes are **Hereditary Spherocytosis (HS)** and **Autoimmune Hemolytic Anemia (AIHA)**. **Why Coombs Test is the correct answer:** The first and most critical step in the diagnostic algorithm for spherocytosis is to differentiate between an inherited membrane defect (HS) and an acquired immune-mediated process (AIHA) [1]. The **Direct Antiglobulin Test (Coombs test)** is the gold standard for this [1]. A positive Coombs test confirms AIHA, while a negative test points toward HS. Since AIHA is a common cause of acquired spherocytosis and requires entirely different management (steroids vs. splenectomy), it must be ruled out first. **Analysis of Incorrect Options:** * **A. Reticulocyte count:** While this will be elevated in any hemolytic anemia, it is non-specific and does not help differentiate the cause of spherocytes. * **B. Osmotic fragility test:** Historically used for HS, this test is now largely replaced by the **EMA Binding test** (Eosin-5-maleimide flow cytometry). Furthermore, osmotic fragility is increased in *both* HS and AIHA, making it less useful than the Coombs test for initial differentiation. * **D. Bone marrow aspiration:** This is generally not indicated in the workup of hemolytic anemias unless a primary bone marrow failure or malignancy is suspected. **NEET-PG High-Yield Pearls:** * **Spherocytes** are smaller, denser RBCs that have lost their central pallor due to loss of surface area [1]. * **Confirmatory test for HS:** EMA Binding test (Most sensitive/specific). * **MCHC:** Characteristically **elevated** (>36 g/dL) in Hereditary Spherocytosis [1]. * **Treatment of choice for HS:** Splenectomy (usually delayed until after age 5-6 to reduce sepsis risk).

Q: Autoimmune hemolytic anemia is associated with malignancy of which lineage?

B cell. **Explanation:** Autoimmune Hemolytic Anemia (AIHA) is most commonly associated with malignancies of the **B-cell lineage**. The underlying pathophysiology involves the production of autoantibodies (IgG in Warm AIHA or IgM in Cold AIHA) by dysfunctional or neoplastic B-lymphocytes. These antibodies target antigens on the surface of red blood cells, leading to their premature destruction [1]. * **Why B cell is correct:** The most frequent association is with **Chronic Lymphocytic Leukemia (CLL)** and **Non-Hodgkin Lymphomas (NHL)** [2], both of which are mature B-cell neoplasms. In CLL, approximately 5–10% of patients develop AIHA due to the loss of immune tolerance and the production of polyclonal autoantibodies. Chronic cold agglutinin disease specifically may be associated with underlying low-grade B cell lymphoma [1]. * **Why T cell is incorrect:** While T-cell lymphomas (like Angioimmunoblastic T-cell Lymphoma) can occasionally be associated with AIHA, they are significantly rarer causes compared to B-cell malignancies [2]. * **Why Pre-B and Pre-T cells are incorrect:** These represent immature precursor cells found in Acute Lymphoblastic Leukemia (ALL). While ALL can cause cytopenias due to marrow infiltration, it is rarely associated with the production of specific anti-erythrocyte autoantibodies. **High-Yield Clinical Pearls for NEET-PG:** 1. **Evans Syndrome:** The clinical triad of AIHA occurring simultaneously or sequentially with Immune Thrombocytopenic Purpura (ITP). 2. **CLL Association:** CLL is the most common malignancy associated with Warm AIHA (IgG mediated). 3. **Direct Antiglobulin Test (Coombs Test):** The gold standard diagnostic test for AIHA. 4. **Infectious Triggers:** Mycoplasma pneumoniae and Infectious Mononucleosis (EBV) are classic triggers for Cold Agglutinin Disease (IgM mediated).

Q: Which of the following is NOT a myeloproliferative disorder?

Hairy cell leukemia. The **Myeloproliferative Neoplasms (MPNs)** are a group of clonal hematopoietic stem cell disorders characterized by the autonomous overproduction of one or more myeloid lineages (erythroid, granulocytic, or megakaryocytic). **Why Hairy Cell Leukemia (HCL) is the correct answer:** Hairy Cell Leukemia is a **mature B-cell lymphoproliferative disorder**, not a myeloproliferative one. It involves the neoplastic proliferation of small B-lymphocytes with characteristic "hairy" cytoplasmic projections. It typically presents with pancytopenia (due to bone marrow fibrosis) and massive splenomegaly, but it originates from the lymphoid lineage. **Why the other options are incorrect:** * **A. Polycythemia Vera (PV):** A classic BCR-ABL negative MPN characterized by erythrocytosis and a *JAK2 V617F* mutation in >95% of cases. * **B. Essential Thrombocytosis (ET):** An MPN characterized by primary megakaryocytic proliferation leading to a high platelet count. Common mutations include *JAK2, CALR,* and *MPL*. * **C. Chronic Myeloid Leukemia (CML):** The prototypical MPN characterized by the Philadelphia chromosome $t(9;22)$ and the *BCR-ABL1* fusion gene, leading to granulocytic overproduction. **Clinical Pearls for NEET-PG:** 1. **MPN Classification:** The four "classic" MPNs are CML, PV, ET, and Primary Myelofibrosis [1]. 2. **HCL Markers:** Look for **TRAP positive** (Tartrate-Resistant Acid Phosphatase) staining and markers like **CD103, CD11c, and CD25**. 3. **HCL Treatment:** The drug of choice is **Cladribine** (a purine analog). 4. **Dry Tap:** Both Hairy Cell Leukemia and Primary Myelofibrosis often result in a "dry tap" on bone marrow aspiration due to extensive fibrosis [1].

Q: During the evaluation of a case of polycythemia, which of the following investigations is LEAST likely to be required to establish the cause?

Serum iron profile. The evaluation of polycythemia focuses on distinguishing between **Primary Polycythemia** (Polycythemia Vera - PV) and **Secondary Polycythemia** (driven by Erythropoietin) [1]. ### Why Serum Iron Profile is the Least Likely Required While iron deficiency can occasionally occur in Polycythemia Vera due to increased red cell production, a **Serum Iron Profile** is not a diagnostic tool to establish the *cause* of polycythemia. In fact, iron deficiency can lead to microcytosis, which might paradoxically mask the rise in hematocrit, but it does not help differentiate between primary and secondary causes. ### Explanation of Other Options * **Erythropoietin (EPO) Level:** This is the initial step in the algorithm. Low EPO levels suggest Polycythemia Vera (Primary), while high levels suggest Secondary Polycythemia (e.g., chronic hypoxia or EPO-secreting tumors). * **Arterial Blood Gas (ABG):** This is crucial to identify **hypoxia-driven secondary polycythemia**. An $SaO_2 < 92\%$ indicates that the polycythemia is a compensatory response to chronic lung disease, cyanotic heart disease, or high altitude [1]. * **Bone Marrow Examination:** In cases where PV is suspected (Low EPO + JAK2 mutation), a bone marrow biopsy is a **WHO major criterion**. It reveals "panmyelosis" (increased cellularity of erythroid, myeloid, and megakaryocytic lines). ### NEET-PG High-Yield Pearls * **WHO Criteria for PV:** Requires 3 Major (High Hb/Hct, BM Panmyelosis, JAK2 mutation) OR 2 Major + 1 Minor (Low Serum EPO). * **JAK2 V617F Mutation:** Present in >95% of PV cases [1]. * **Spurious Polycythemia (Gaisbock Syndrome):** Seen in stressed, hypertensive, obese males due to decreased plasma volume rather than increased red cell mass [1]. * **Rule of Thumb:** If EPO is high, look at the lungs (ABG) or kidneys (Ultrasound for Renal Cell Carcinoma).

Q: Calculate the total iron deficit for a 50 kg person with a hemoglobin level of 5 g/dL, including an additional 1000 mg for iron stores.

2150 mg. ### Explanation The calculation of iron deficiency is a high-yield topic for NEET-PG, typically determined using the **Ganzoni Formula**. This formula calculates the total iron deficit required to restore hemoglobin to a target level and replenish iron stores. **The Ganzoni Formula:** $\text{Total Iron Deficit (mg)} = \text{Body weight (kg)} \times (\text{Target Hb} - \text{Actual Hb}) \times 2.4 + \text{Iron stores (mg)}$ *Note: Target Hb is usually taken as 15 g/dL for adults.* **Step-by-Step Calculation:** 1. **Weight:** 50 kg 2. **Hb Deficit:** $(15 - 5) = 10 \text{ g/dL}$ 3. **Iron for Hb restoration:** $50 \times 10 \times 2.4 = 1200 \text{ mg}$ 4. **Iron for Stores:** Given as $1000 \text{ mg}$ 5. **Total Deficit:** $1200 + 1000 = \mathbf{2200 \text{ mg}}$ While the mathematical result is 2200 mg, **Option A (2150 mg)** is the closest clinical approximation provided. In some variations of the formula, a target Hb of 14.8 g/dL is used, which yields exactly 2176 mg, making 2150 mg the most appropriate choice. **Analysis of Incorrect Options:** * **Option B (1650 mg):** This value is too low; it likely underestimates the Hb deficit or uses an insufficient constant. * **Option C (1150 mg):** This represents only the iron needed for Hb restoration without adding the 1000 mg for stores. * **Option D (1575 mg):** This is a mathematical error often resulting from using an incorrect constant (e.g., 0.66 instead of 2.4). **Clinical Pearls for NEET-PG:** * **The Constant 2.4:** Derived from the blood volume (approx. 7% of body weight) and the iron content of hemoglobin (0.34%). * **Parenteral Iron:** Indicated in cases of oral iron intolerance, malabsorption (e.g., Celiac disease), or when rapid replenishment is needed (e.g., 3rd-trimester pregnancy) [1]. * **Iron Stores:** Always assume 500–1000 mg for adults unless specified otherwise [2]. For children, use 15 mg/kg.

Question 1

What is an indication for intramuscular iron therapy?

Accepted Answer

Oral iron intolerance

Answer

Pregnancy

Answer

Postpartum period

Answer

Emergency surgery

Question 2

Paroxysmal Nocturnal Hemoglobinuria (PNH) is screened by which of the following tests?

Accepted Answer

Acid ham test

Answer

Sucrose lysis test

Answer

Serum hapten levels

Answer

Low serum complement levels

Question 3

A 23-year-old female presents with a 2-year history of anemia and jaundice. A peripheral smear shows spherocytes. What is the most appropriate investigation to perform?

Accepted Answer

Coombs test

Answer

Reticulocyte count

Answer

Osmotic fragility test

Answer

Bone marrow aspiration

Question 4

Autoimmune hemolytic anemia is associated with malignancy of which lineage?

Accepted Answer

B cell

Answer

T cell

Answer

Pre B cell

Answer

Pre T cell

Question 5

Which of the following is NOT a myeloproliferative disorder?

Accepted Answer

Hairy cell leukemia

Answer

Polycythemia vera

Answer

Essential thrombocytosis

Answer

Chronic myeloid leukemia

Question 6

During the evaluation of a case of polycythemia, which of the following investigations is LEAST likely to be required to establish the cause?

Accepted Answer

Serum iron profile

Answer

Erythropoietin level

Answer

Arterial blood gas analysis

Answer

Bone marrow examination

Question 7

A patient with thalassemia major on repeated packed RBC transfusions and iron chelation therapy presents with a history of arrhythmias. During the current transfusion, she develops backache and appears anxious. What is the most appropriate next step in management?

Accepted Answer

Stop the transfusion and perform a clerical check of the blood group

Answer

Observe for changes in urine color

Answer

Continue the transfusion and perform an ECG

Answer

Stop the transfusion and wait for the patient to stabilize before resuming

Question 8

What is Evan's syndrome?

Accepted Answer

Immune thrombocytopenic purpura with autoimmune hemolytic anemia

Answer

Immune thrombocytopenic purpura with cryoglobulinemia

Answer

Immune thrombocytopenic purpura with spherocytosis

Answer

Immune thrombocytopenic purpura with myelodysplastic syndrome

Question 9

Calculate the total iron deficit for a 50 kg person with a hemoglobin level of 5 g/dL, including an additional 1000 mg for iron stores.

Accepted Answer

2150 mg

Answer

1650 mg

Answer

1150 mg

Answer

1575 mg

Question 10

Which of the following is true about hemochromatosis?

Accepted Answer

It is associated with diabetes mellitus and slate grey discoloration of the skin.

Answer

It causes iron deficiency anemia.

Answer

Kayser Fleischer rings are seen in the eyes.

Answer

Autosomal dominant inheritance is the most common form.

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?